FBIO
Fortress Biotech Inc
2.30$
-2.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.3% | -1.7% | -11.5% | -12.8% | +13.5% | +23.5% | -10.2% | +13.5% | +2.3% | +92.3% | -11.3% | |
| – | +19.6% | -0.4% | -11.3% | -16.6% | +4.7% | +40.4% | -13.0% | +7.3% | +4.5% | +138.6% | -16.9% | |
| – | +8.3% | +6.1% | -11.2% | -22.8% | -2.7% | +59.5% | -18.6% | +15.9% | -7.9% | +222.3% | -23.2% | |
| – | +8.3% | +6.1% | -11.2% | -22.8% | -2.7% | +59.5% | -18.6% | +15.9% | -7.9% | +222.3% | -23.2% | |
| – | +88.7% | -34.2% | +5.6% | +1.5% | -4.1% | +76.3% | -11.6% | +11.9% | +65.2% | -14.8% | +44.1% | |
| – | -7.4% | +3.7% | -8.4% | +21.7% | +22.4% | -13.4% | +2.8% | -8.0% | -18.6% | -3.4% | -12.2% | |
| – | -3.9% | -4.0% | -4.2% | -4.4% | +78.6% | -3.3% | -3.5% | -3.6% | -3.7% | -4.1% | -3.7% | |
| – | +1.3% | +1.6% | -4.9% | -12.8% | +4.3% | -0.2% | -15.8% | -5.1% | +6.1% | +25.2% | -28.4% | |
| – | -12.8% | +3.3% | -13.9% | -6.9% | +1.6% | +3.2% | -21.9% | -6.0% | -8.0% | +107.9% | -40.0% | |
| – | -40.0% | +74.2% | -43.0% | -31.3% | -13.7% | +24.2% | +46.0% | +31.6% | -72.6% | +122.0% | +53.5% | |
| – | -22.2% | +20.1% | -9.2% | -10.3% | -7.0% | -12.1% | -27.4% | -7.0% | -24.1% | -0.7% | -16.1% | |
| – | +32.9% | +0.9% | +9.1% | -21.7% | +10.5% | -2.7% | -11.3% | -4.5% | +24.5% | -38.0% | -6.2% | |
| – | +35.2% | +2.1% | -22.4% | +18.4% | +7.5% | -2.1% | +97.4% | +27.2% | -10.7% | +225.2% | +1.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.1% | +119.8% | +6.8% | +7.5% | +2.8% | +30.7% | +12.8% | +11.0% | +8.0% | +7.4% | -3.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.